To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.

 
 

Description

The purpose of this case report is to highlight the emergence of a rare adverse drug reaction (ADR), euglycemic diabetic ketoacidosis (EDKA), associated with the use of sodium glucose transport 2 (SGLT2) inhibitors.EDKA is a rare and often misdiagnosed condition, due to the absence of hyperglycemia, but represents a life-threatening emergency. We present a unique case of a 35-year-old female patient with a past medical history of diabetes and recent diagnosis of Hashimoto’s thyroiditis. The primary objective is to provide valuable insights and education to the medical community regarding this infrequent yet significant complication. Ultimately, the goal is to enhance future patient care by improving awareness and promoting informed decision-making in EDKA cases involving SGLT2 inhibitors.

Disciplines

Health Services Research | Medical Education | Medical Sciences | Medicine and Health Sciences

Document Type

Event

Download

Share

COinS
 

Euglycemic diabetic ketoacidosis secondary to Sodium Glucose 2 Transport Inhibitor: a case report

The purpose of this case report is to highlight the emergence of a rare adverse drug reaction (ADR), euglycemic diabetic ketoacidosis (EDKA), associated with the use of sodium glucose transport 2 (SGLT2) inhibitors.EDKA is a rare and often misdiagnosed condition, due to the absence of hyperglycemia, but represents a life-threatening emergency. We present a unique case of a 35-year-old female patient with a past medical history of diabetes and recent diagnosis of Hashimoto’s thyroiditis. The primary objective is to provide valuable insights and education to the medical community regarding this infrequent yet significant complication. Ultimately, the goal is to enhance future patient care by improving awareness and promoting informed decision-making in EDKA cases involving SGLT2 inhibitors.